AURA

Aura Biosciences, Inc. (AURA) SWOT Analysis Analysis (2026)

Invetso Score: 3.4/10 — Weak · Last Updated: 2026-08-01

Strengths

AURA’s current ratio of 16.8x indicates exceptional near-term liquidity versus peers, reducing refinancing pressure and supporting operational continuity.

Net debt to EBITDA of 0.39x suggests modest leverage relative to peers, which preserves balance-sheet flexibility despite weak profitability.

Cash conversion cycle of 0 implies efficient working-capital management, limiting cash drag and improving resilience versus peers with longer cycles.

Weaknesses

Return on invested capital of -41.6% signals severe capital destruction, leaving AURA structurally behind profitable peers on value creation.

The absence of reported operating and gross margins limits visibility, but the negative ROIC implies the core business is not yet monetizing capital efficiently.

Debt-to-equity of 0.05x is low, yet the balance sheet advantage is outweighed by weak returns, so peers with positive profitability remain stronger.

Opportunities

If AURA converts its strong liquidity into profitable growth, peers with tighter working capital would face less strategic flexibility over the next 2–5 years.

Low leverage creates room to fund product, capacity, or market expansion without stressing the balance sheet, unlike more indebted peers.

A zero cash conversion cycle provides a base for scaling operations efficiently, which could narrow the gap versus peers if demand improves.

Threats

Persistent negative ROIC threatens long-term competitiveness because peers with positive capital returns can reinvest faster and compound market share.

Without disclosed margin data, investors may continue to discount AURA versus peers, since profitability visibility is a key structural differentiator.

Strong liquidity can mask operating weakness, but if returns stay negative, peers with better economics will sustain a superior structural position.

Overall Score

AURA’s balance sheet is liquid and lightly levered, but deeply negative capital returns leave its structural positioning materially weaker than profitable peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Aura Biosciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →